Pharmacokinetics for once‐daily versus twice‐daily tacrolimus formulations in de novo liver transplantation: A randomized, open‐label trial
Lutz Fischer, Pavel Trunečka, Bruno Gridelli, Andre Roy, Alessandro Vitale, Andrés Valdivieso, Evaristo Varo, Daniel Seehofer, Stephen Lynch, Didier Samuel, Bo‐Goran Ericzon, Karim Boudjema, Carmen Karpf, Nasrullah Undre – 21 October 2010 – Tacrolimus, a cornerstone immunosuppressant, is available as a twice‐daily formulation (tacrolimus bid). A once‐daily prolonged‐release formulation (tacrolimus qd) has been developed.